Hello to the listeners, my name is Jan Wagner and I am a medical student from Oldenburg, Germany. Thank you very much for the invitation and for allowing me to report on our study results to the IASLC. The title of the study is Evaluation of the Prognostic Marker of PD-L1 Expression after Combined Radiochemotherapy in NSCLC Stage 3. There is no conflict of interest. You probably know the specific study which showed that patients with NSCLC had a survival advantage and a longer present free period when they were treated with the PD-L1 inhibitor Doradumab. Interestingly, the study showed that the overall survival of the PD-L1 negative patients in the control arm was significantly more favorable than the patient control arm with an expression of at least one percent. This could indicate that the PD-L1 expression is a prognostic factor in NSCLC after radiochemotherapy. So to test this hypothesis, we simulated the control arm of the specific study and examined the influence of PD-L1 as a prognostic factor. So we took the clinical data and characteristics from the Peel's Hospital tumor database. 99 patients were included and if no PD-L1 test was carried out so far, this was analyzed afterwards. We made sure to create the same condition as in the specific study. For example, we also used the same antibody for the PD-L1 analysis. In addition, further clinical characteristics were collected from the database. So here are the first results. 99 patients were included in the study. Of these, 64 were male and 35 were female. In tumor histology, there were slightly more cases of Lanscremas, Lanscremas lung cancer. And as often described in the literature, the PD-L1 expression were distributed as follows. 34 patients had a value below 1% and 65 had a value greater than or equal to 1%. So on this slide, you can see the Kaplan-Meier curves according to PD-L1 status. On the left, you can see the curve for OS or survival in month. And on the right, you can see the curve for PFS, progress-free survival in month. The OS differed in the groups. For PD-L1 values below 1%, it was 20 month confidence interval 10.5 to 29.5. And for values greater than or equal to 1, 28 month confidence interval 16.5 to 39.3. It was similar with PFS. Values below 1%, the PFS was 9 month confidence interval 6.4 to 11.6. And for values below or equal to 1%, it was 12 month confidence interval 9.8 to 14.2. So as you have seen in the previous slide, the respective curves have intersected. In addition, the P values were not significant in each case. We also evaluated the blood values of CRP, albumin, and the CRP-albumin quotient and checked whether it had an influence on the OS or not. First of all, no significant difference could be seen here either. But the OS was as follows for the CRP. With values below 5.61 milligram per liter, the OS was 30 month. And with values greater than or equal to 5.61, it was 15 month with a P value of 0.09. Studies have already shown that CRP has an impact on overall survival. This is also comprehensible here and possibly also significantly reproducible in a larger patient collective. So the aim of the study was to examine the presumption made in the PACIFIC study. For this purpose, the best possible attempt was made to simulate a study arm and to minimize the weakness from the PACIFIC study, such as the fact that not all patients were tested, difficulties in getting samples after radiochemotherapy. After analyzing and considering the clinical characteristics and the endpoints, it can be determined that there is no significant difference. It must therefore be assumed that PD-L1 expression cannot provide a reliable prognosis for OS and PFS. In order to strengthen the statement, a further study with a larger patient collective would be advantageous. Lastly, I want to thank everyone for listening and many thanks to the research group of Professor Griesinger for their support in the study.

PD-L1 expression

prognostic marker

combined radiochemotherapy

NSCLC Stage 3

clinical data